Biomarker analysis from a Phase 1/1b study of tusamitamab ravtansine in patients with advanced non-small cell lung cancer
Authors
- Dimitri Carène
- Emma Wang (ORCID: https://orcid.org/0000-0002-5200-1043)
- Anas Gazzah (ORCID: https://orcid.org/0000-0002-6866-6787)
- Mustapha Chadjaa (ORCID: https://orcid.org/0009-0009-1376-8872)
- Nils Ternès
- Gaëlle Muzard
- Aude Lartigau
- Eric Boitier
- Colette Dib
- Nina Masson (ORCID: https://orcid.org/0009-0001-6665-6032)
- Nathalie Mace
- Hong Wang (ORCID: https://orcid.org/0000-0003-0477-2908)
- Manoel Nunes
- Joon Sang Lee
- Anne-Laure Bauchet
- Sandrine Longuemaux-Valence
Institutions
- Institut Gustave Roussy (FR)
- Sanofi (France) (FR)
- Sanofi (United States) (US)